Bee Honey and Functional Dyspepsia in Children
Functional Gastrointestinal Disorders
About this trial
This is an interventional treatment trial for Functional Gastrointestinal Disorders focused on measuring Functional dyspepsia in children, Bee honey
Eligibility Criteria
Inclusion Criteria:
- All patients between 8 and 18 years-old, based on Rome IV criteria that provide evidence-based definitions and classifications for so-called functional gastrointestinal disorders, such as functional dyspepsia in children and adolescents, with 1 or more of the following bothersome symptoms at least 4 days per month for at least 2 months:
- Postprandial fullness
- Early satiation
- Epigastric pain or burning not associated with defecation
- After appropriate evaluation, the symptoms cannot be fully explained by another medical condition
- Postprandial distress syndrome includes bothersome postprandial fullness or early satiation that prevents finishing a regular meal. Supportive features include upper abdominal bloating, postprandial nausea, or excessive belching.
- Epigastric pain syndrome, which includes all of the following: bothersome (severe enough to interfere with normal activities) pain or burning localized to the epigastrium. The pain is not generalized or localized to other abdominal or chest regions and is not relieved by defecation or passage of flatus. Supportive criteria can include (a) burning quality of the pain but without a retrosternal component and (b) the pain commonly induced or relieved by ingestion of a meal but may occur while fasting.
Exclusion Criteria:
- The presence of alarm symptoms and signs which might suggest underlying organic pathology as listed in Rome III criteria including: (Persistent right upper or right lower quadrant pain, dysphagia, persistent vomiting, gastrointestinal blood loss, nocturnal diarrhea, family history of inflammatory bowel disease, celiac disease, or peptic ulcer disease, pain that wakes the child from sleep, arthritis, perirectal disease, involuntary weight loss, deceleration of linear growth, delayed puberty or unexplained fever).
- Gastrointestinal tract surgery, one year post-operative.
- Diabetes mellitus
- Any debilitating disorder e.g. malignancy, severe malnutrition, renal failure, etc.
- Patients on medications that may produce GIT disorders e.g. aspirin, steroids or NSAIDs
Sites / Locations
- Ain Shams University
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Trial (Intervention) group
Control (Non-intervention) group
Patients will receive honey for 8 weeks in a dose of 30 ml undiluted honey per day divided as 5 ml honey 30 minutes before each meal six times daily. The honey will be kept in a closed glass container and away from light until the time of use. Each patient will be provided with a well-sealed container containing 210 ml honey each week. The honey used in the study will be a raw, unprocessed Clover honey collected from AL Mahala-Gharbia governorate, Egypt. The honey will be supplied directly from a beekeeper without heating or gamma irradiation
No honey will be given to this group